{"id":547,"date":"2025-05-08T17:34:10","date_gmt":"2025-05-08T15:34:10","guid":{"rendered":"https:\/\/www.nutrimedia.info\/?post_type=news&p=547"},"modified":"2025-04-23T17:34:23","modified_gmt":"2025-04-23T15:34:23","slug":"glp-1-the-tsunami-sweeping-away-traditional-slimming-diets","status":"publish","type":"news","link":"https:\/\/www.nutrimedia.info\/en\/news\/glp-1-le-tsunami-qui-balaie-les-regimes-minceur-traditionnels\/","title":{"rendered":"GLP-1, the new game-changer in nutrition?"},"content":{"rendered":"

In 2025, the food industry is facing a major transformation. The rise of GLP-1 agonist drugs such as Ozempic is revolutionising eating habits and the expectations of many consumers. This pharmacological revolution is forcing industry professionals to rethink their strategies in terms of nutrition, marketing and product development.<\/strong>. Decoding<\/strong>.<\/p>\n\n\n\n

GLP-1: a catalyst for dietary change<\/strong><\/h2>\n\n\n\n

GLP-1 drugs, originally developed to treat type 2 diabetes, are now widely used for weight loss. Their success is such that they are now rare in pharmacies and are subject to stricter controls on prescribing. Their mechanism of action reduces appetite and slows gastric emptying, leading to a significant reduction in food consumption. <\/p>\n\n\n\n

Mut are they really effective?<\/strong>
The debate continues to animate medical and media circles. And yet.., the scientific evidence is increasingly categorical<\/strong>. Several rigorous randomised clinical trials now confirm the efficacy of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists in inducing significant weight loss, often greater than that observed with conventional approaches.<\/p>\n\n\n\n

As a result, their use is exploding worldwide. The reason for this is a double advantage rarely found in this field: proven clinical efficacy and generally well-controlled tolerability<\/strong>. The market is following suit: prescriptions are increasing, investment is flowing in, and the food industry is already adapting. Yes, you read that right.<\/p>\n\n\n\n

\n

According to a Mintel study, users of these drugs are adopting new eating habits, seeking out protein-rich foods in small portions that encourage hydration.<\/p>\n<\/blockquote>\n\n\n\n

What does this mean for you?<\/strong><\/h2>\n\n\n\n

1. Product reformulation<\/strong><\/h3>\n\n\n\n

Adaptation is gradually becoming a necessity, as we have to meet the new expectations of consumers on GLP-1 treatment, who are, it's true, increasingly numerous. This means reducing portions, increasing nutritional density and paying particular attention to satiety, with more proteins<\/a> plant and\/or animal.<\/p>\n\n\n\n

2. Transparent communication<\/strong><\/h3>\n\n\n\n

Transparency about the composition of products is becoming essential. Increasingly well-informed consumers are demanding clear information on the nutritional values and health benefits of food.<\/p>\n\n\n\n

3. Product innovation<\/strong><\/h3>\n\n\n\n

Innovation should focus on products that complement the action of GLP-1 drugs, such as protein-rich snacks, functional drinks and balanced ready-to-eat meals.<\/p>\n\n\n\n

Some key data<\/strong><\/h2>\n\n\n\n